StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Oh here's some real information not opinion

<< Previous

Bullboard Posts

Next >>

Comment by Jonnyboy85on Apr 27, 2021 2:19pm

98 Views

Post# 33075582

RE:Oh here's some real information not opinion

Jonnyboy85 wrote:

StageZero Life Sciences Announces Q4 2020 and Year End Financial Results and Operational Update

April 01, 2021

Q4 Revenue of $2.82 Million

TORONTO, ON / ACCESSWIRE / April 1, 2021 / StageZero Life Sciences, Ltd. (TSX:SZLS) ("StageZero" or the "Company") reports financial results for the three and twelve months ended December 31, 2020, and provides an update on its business progress.

"Fourth quarter revenues are up significantly from Q3 and increased more than $2.54 million compared with the fourth quarter of 2019. This builds on our third quarter results and the Company's decision to offer COVID-19 testing. The Company received $2.82 million revenue during Q4 2020, which amount included revenue deferred into 2021 of $0.23 million" said James Howard-Tripp, Chairman and CEO of StageZero.

Operational Update and Recent Highlights
The following milestones were achieved during the fourth quarter:

Received revenue of $2.82 million for the period.

Closed a prospectus offering of more than C$7M.

Hired additional staff and purchased equipment, test reagents, and consumable materials (for COVID-19 Tests and Aristotle®).

The following has been achieved in the first quarter of 2021:

Aristotle launched as part of the AVRT Program

Acquisition of Health Clinics Limited

Expanded testing in Canada via the Company's partnership with Ichor Blood Services.

Hired further staff and expanded testing capacity, both for COVID-19 and Aristotle®.

Participated in two investor focused conferences.

"Revenue from 2020 and 2021 supports the Company's efforts for commercialization and marketing of AVRT and Aristotle" said James Howard-Tripp, Chairman and CEO of StageZero. "We are pleased to have Health Clinics and Care Oncology as our partner, with the infrastructure in place, to support the uptake of these very innovative products"